Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-MSCs for Female Sexual Function Impairment
NCT05329662Phase 2Recruiting
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
- Start
- May 2023
- Primary completion
- Jun 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous adipose-derived mesenchymal stromal cells in female sexual dysfunction (FSD) (2 arms), sponsored by Vinmec Research Institute of Stem Cell and Gene Technology. Primary endpoints: Follicle-stimulating hormone at 12 months, Estradiol at 12 months and 2 more. Started May 2023; status: recruiting.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
female sexual dysfunction (FSD)
Beyond the preview
Go deeper on NCT05329662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329662.